$1.79
-0.14-7.25%
Last update: Nov 12, 7:36 AM
Ernexa Therapeutics Inc (ERNA) Stock Price, Quote, News & History
ERNANASDAQ
Ernexa Therapeutics reports independent preclinical validation of ERNA-101 with PD-1 therapy ahead of the planned 2026 IND filing.
You can purchase shares of Ernexa Therapeutics (NASDAQ:ERNA) through any online brokerage.
Other companies in Ernexa Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Ernexa Therapeutics has a consensus price target of $30.00.
The stock price for Ernexa Therapeutics (NASDAQ: ERNA) is $1.86 last updated November 12, 2026 at 7:36 AM EST.
There are no upcoming dividends for Ernexa Therapeutics.
Ernexa Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Ernexa Therapeutics.
Ernexa Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the...
